ArticleCancer immunology research2018
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Article in Cancer immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- L-ICON3 Suppresses Endometriosis in a Murine Model.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer.International journal of molecular sciences · 2025Article
- CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors.Vaccines · 2025Review
- Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma.Oncogene · 2025Article
- Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format.Cancer immunology, immunotherapy : CII · 2024Article
- Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.Frontiers in immunology · 2024Review
- Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023Review
- Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer.Biomarker research · 2023Review
- Review
- Tissue factor as a new target for tumor therapy-killing two birds with one stone: a narrative review.Annals of translational medicine · 2022Review
- Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?BMC cancer · 2022Article
- Regulation of Tissue Factor by CD44 Supports Coagulant Activity in Breast Tumor Cells.Cancers · 2022Article
- Tissue factor: a neglected role in cancer biology.Journal of thrombosis and thrombolysis · 2022Review
- Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer.Cancers · 2021Review
- Review
- Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.Medicina (Kaunas, Lithuania) · 2021Review
- Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells.Frontiers in oncology · 2021Article
- Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer.Molecules (Basel, Switzerland) · 2020Review
- Beyond thrombosis: the impact of tissue factor signaling in cancer.Journal of hematology & oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a leading cause of breast cancer death and is often associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.